By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS‑4729 has received clinical trial approval from the National Medical Products Administration (NMPA) to proceed with Phase II clinical trials in adult patients with type 2 diabetes. The clearance advances one of China’s growing pipeline of next‑generation incretin‑based metabolic therapies.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval – Phase II |
| Product | HRS‑4729 (self‑developed peptide drug; triple agonist) |
| Indication | Type 2 diabetes in adult patients |
| Announcement Date | 12 Aug 2026 |
| Next Steps | Initiation of Phase II studies assessing efficacy and safety in adults with type 2 diabetes |
Drug Profile & Mechanism of Action
- Molecule: HRS‑4729, a self‑developed peptide drug functioning as a triple agonist
- Targets: Simultaneously activates three metabolic receptors — GLP‑1R (glucagon‑like peptide‑1 receptor), GIPR (glucose‑dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor)
- Pharmacological Actions: Suppresses appetite, delays gastric emptying, enhances insulin sensitivity, and increases energy expenditure in vivo
- Therapeutic Effects: Combined actions promote weight loss, glycemic control, and improved glucose and lipid metabolism, ultimately achieving therapeutic efficacy in treating type 2 diabetes
Market Impact & Outlook
- Next‑Generation Incretin Race: Triple agonism targeting GLP‑1R/GIPR/GCGR represents the frontier beyond currently dominant single and dual agonists, with the glucagon component designed to drive additional energy expenditure and lipid benefits.
- Massive Addressable Market: China has the world’s largest type 2 diabetes population, and demand for therapies combining glycemic control with weight reduction continues to expand rapidly.
- Competitive Positioning: With domestic leaders and global players alike pursuing multi‑agonist approaches, HRS‑4729’s Phase II entry keeps Hengrui Pharmaceuticals in the leading pack of China’s incretin‑based drug race.
- Portfolio Strength: The approval reinforces Hengrui’s strategy of building a broad metabolic disease franchise on top of its established oncology pipeline, leveraging its in‑house peptide drug discovery capabilities.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial conduct, efficacy outcomes, and commercial potential for HRS‑4729. Actual results may differ due to risks including Phase II safety and efficacy data, regulatory decisions, and competitive dynamics in the metabolic disease market.-Fineline Info & Tech